CONSHOHOCKEN, PA — IntrinsiQ Specialty Solutions, a division of Cencora, announced the expansion of its data and analytics offerings to include oncology biomarker data and new insights across multiple therapeutic areas, including retina care. The enhancements aim to give healthcare providers and pharmaceutical manufacturers deeper visibility into real-world treatment patterns and outcomes.
The inclusion of oncology biomarker data represents a step toward precision medicine, allowing physicians to move beyond generalized treatment protocols and customize cancer therapies to individual patients. By integrating these data-driven insights, IntrinsiQ seeks to help clinicians improve care decisions and optimize outcomes for patients while advancing innovation in specialty medicine.
Through its established relationships with community providers, IntrinsiQ aggregates data that reveal how therapies are being used in practice—offering manufacturers a clear view of treatment adoption, continuation, and performance once products enter the market. These insights, informed by both clinical data and feedback from care teams, are used to support targeted education, improve physician engagement, and enhance patient care.
Scott Morris, President and General Manager of IntrinsiQ, said the company’s expanded capabilities are designed to bridge information gaps between providers and manufacturers. “We have a strong understanding of the challenges providers face, as well as the unique ability to bridge that gap by providing real-world data and insights into how therapies are being used in the field,” he said. “Our enhanced data capabilities and insights enable our partners and customers to tap into their data’s full potential, transforming raw information into strategic insights that can drive innovation, education, and most importantly, improved patient outcomes.”
Lisa Harrison, President of Specialty Distribution and Solutions at Cencora, said the expansion reinforces the company’s commitment to advancing care coordination across the healthcare landscape. “As a trusted partner to manufacturers and providers alike, Cencora is committed to deepening its relationships across the healthcare ecosystem to drive positive pharmaceutical outcomes,” Harrison said. “By leveraging an industry-leading portfolio and extensive data from our end-to-end solutions, we’re helping manufacturers, clinicians, and patients navigate the complexities of the pharmaceutical landscape, ensuring therapies reach the right patients at the right time.”
With these advancements, IntrinsiQ continues to position itself as a key data intelligence partner in specialty care, providing life sciences companies with actionable insights that improve decision-making and patient outcomes in an increasingly complex treatment environment.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.